de Jong F H, Reuvers P J, Bolt-de Vries J, Mulder E, Blom J H, Schroeder F H
Department of Endocrinology and Reproduction, Erasmus University Rotterdam, The Netherlands.
J Steroid Biochem Mol Biol. 1992 Mar;42(1):49-55. doi: 10.1016/0960-0760(92)90010-g.
Testosterone, 5 alpha-dihydrotestosterone and cyproterone acetate (CPA) were estimated in samples of prostate tissue, obtained from benign prostatic hyperplasia (BPH) patients who were or were not pretreated with CPA. Furthermore, these steroids were estimated in various fractions of the BPH tissue, and the number of nuclear androgen-receptor sites was determined. CPA-treatment caused a 4-fold, significant suppression of 5 alpha-dihydrotestosterone levels in total prostate tissue and its subfractions, without affecting testosterone levels or the androgen-receptor contents of the nuclear extracts. Nuclear concentrations of CPA were twice as high as those of 5 alpha-dihydrotestosterone. It is concluded that effects of CPA may have been caused through a combination of the following mechanisms: (1) suppression of peripheral androgen levels; (2) competition with androgens for (nuclear) androgen-receptors; and (3) suppression of prostatic 5 alpha-reductase.
对取自接受或未接受醋酸环丙孕酮(CPA)预处理的良性前列腺增生(BPH)患者的前列腺组织样本中的睾酮、5α-二氢睾酮和醋酸环丙孕酮(CPA)进行了测定。此外,还对BPH组织的各个部分中的这些类固醇进行了测定,并确定了核雄激素受体位点的数量。CPA治疗使整个前列腺组织及其亚组分中的5α-二氢睾酮水平显著降低了4倍,而不影响睾酮水平或核提取物中的雄激素受体含量。CPA的核浓度是5α-二氢睾酮的两倍。得出的结论是,CPA的作用可能是通过以下机制共同作用引起的:(1)抑制外周雄激素水平;(2)与雄激素竞争(核)雄激素受体;(3)抑制前列腺5α-还原酶。